USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization
CNS Neuroscience & Therapeutics · 2024-04 · 30 (4)
DOI: 10.1111/cns.14711 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 21.04.2024. Verfasst von Jiaqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Temozolomide, DNA Repair Enzymes, DNA Modification Methylases, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To elucidate the relationship between USP19 and O(6)‐methylguanine‐DNA methyltransferase (MGMT) after temozolomide treatment in glioblastoma (GBM) patients with chemotherapy resistance.
Methods
Screening the deubiquitinase pannel and identifying the deubiquitinase directly interacts with and deubiquitination MGMT. Deubiquitination assay to confirm USP19 deubiquitinates MGMT. The colony formation and tumor growth study in xenograft assess USP19 affects the GBM sensitive to TMZ was performed by T98G, LN18, U251, and U87 cell lines. Immunohistochemistry staining and survival analysis were performed to explore how USP19 is correlated to MGMT in GBM clinical management.
Results
USP19 removes the ubiquitination of MGMT to facilitate the DNA methylation damage repair. Depletion of USP19 results in the glioblastoma cell sensitivity to temozolomide, which can be rescued by overexpressing MGMT. USP19 is overexpressed in glioblastoma patient samples, which positively correlates with the level of MGMT protein and poor prognosis in these patients.
Conclusion
The regulation of MGMT ubiquitination by USP19 plays a critical role in DNA methylation damage repair and GBM patients’ temozolomide chemotherapy response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- State Key Laboratory of Cardiology and Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
ORCID-Profile: Jiaqi Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Wang, K., Zhu, Q., Zhang, Y., Chen, Y., Lou, Z., & Yuan, J. (2024). USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization. CNS Neuroscience & Therapeutics, 30(4). https://doi.org/10.1111/cns.14711
Vancouver
Liu J, Wang K, Zhu Q, Zhang Y, Chen Y, Lou Z, et al. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization. CNS Neuroscience & Therapeutics. 2024;30(4). doi:10.1111/cns.14711
BibTeX
@article{Liu2024,
author = {Liu, Jiaqi and Wang, Kaikai and Zhu, Qian and Zhang, Yixin and Chen, Yuping and Lou, Zhenkun and Yuan, Jian},
title = {USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {4},
doi = {10.1111/cns.14711}
}
EUVIMED